SBIR Phase I: Development of biocompatible and biodegradable UV filters based on food-grade protein sources
SBIR 第一阶段:开发基于食品级蛋白质来源的生物相容性和可生物降解的紫外线过滤剂
基本信息
- 批准号:2136707
- 负责人:
- 金额:$ 25.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:Standard Grant
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-15 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) project is the development of novel sunscreens and UV-protective products that are safer for both humans and the environment. Sunscreen protects the skin by absorbing or reflecting the sun’s harmful UV rays,preventing premature skin aging, painful burns, and skin cancer, which is the most common form of cancer in the U.S., and results in treatment costs reaching $3.3 billion annually. UV-filtering active ingredients in sunscreens have been under scrutiny because of the safety risks they pose to humans and the environment. Current UV filters can be absorbed by the skin, cause hormone disruption, and persist and accumulate in the environment, where they can harm wildlife and disrupt marine ecosystems. This project will advance the development of novel sunscreens and UV filters composed of naturally occurring, food-safe peptides containing UV-absorbing amino acids. These compounds are photo-stable, biodegradable, non-absorbing, and safe for both humans and the environment, and they will have high impact in the fields of skin care and biosafe food packaging. Because they can be produced at relatively low cost, they also have the potential to take a considerable share of the $13 billion sunscreen industry.This SBIR Phase I project proposes to complete the following objectives: 1) Develop sunscreen peptides from widely available food-grade sources and scale to 100 g to show cost-competitiveness with current xenobiotic sunscreen compounds and reproducibility; 2) Optimize peptides to improve their UVabsorbance and investigate heterologous expression in bacteria; and 3) Evaluate peptide chemical stability, photo-stability, and confirm non-absorption. This will achieve the overall Phase I goal of reproducibly generating safe and biodegradable UV-absorbing peptides at the 100 g scale, with initial stability studies conducted. This work will lay the foundation for future efforts including independent safety studies, kg-scale production, and clinical trials to result in the first new over-the-counter sunscreen active ingredient introduced in over 35 years.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
这项小型企业创新研究(SBIR)项目的更广泛的影响/商业潜力是开发新颖的防晒霜和紫外线保护产品,这些产品对人类和环境都更安全。防晒霜通过吸收或反映太阳有害的紫外线,防止皮肤过早,疼痛的灼伤和皮肤癌来保护皮肤,这是美国最常见的癌症形式,并导致治疗成本达到33亿美元的紫外线过滤,因为在防晒霜中,在防晒霜中遭受了限制,因为他们受到了审查的限制,因为他们的安全风险是他们的安全风险。当前的紫外线过滤器可能会被皮肤吸收,引起骑马的破坏,并在环境中持续和丙烯酸,在那里它们会损害野生动植物并破坏海洋生态系统。该项目将推动新型防晒霜和紫外线过滤器的开发,这些防晒霜和紫外线过滤器由含有紫外线氨基酸的天然食品安全胡椒粉组成。这些化合物对人类和环境都是照相稳定,可生物降解,不吸收和安全的,它们将在皮肤护理和生物安全食品包装领域产生很大的影响。因为它们可以以相对较低的成本生产,所以它们也有可能考虑在130亿美元的防晒工业中占有一部分。该SBIR I期项目的项目提案要完成以下对象:1)从广泛可用的食品量来源开发防晒肽,并扩展到100 g至100 g,以表现出与当前Xenobiotic cunscreencreencreencreencreencreencreencrencreencreencrenscrencrenscreencrenscornitive and Scemitive comploce; 2)优化Petides以改善其紫外线并研究细菌中的异源表达; 3)评估肽化学稳定性,光稳定性并确认不吸收。这将实现I阶段的整体目标,即在100 g量表上可重复地产生安全和可生物降解的紫外线,并进行初始稳定性研究。这项工作将为未来的努力奠定基础,包括独立的安全研究,KG规模的生产和临床试验,从而导致了35年以上引入的首个新的非处方防晒霜活跃成分。该奖项反映了NSF的法定任务,并被认为是通过使用该基金会的智力和更广泛影响的评估来审查Criteria通过评估来通过评估来获得支持的。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Micah Nelp其他文献
Micah Nelp的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
闪电先导和回击阶段针状结构发生发展特征差异研究
- 批准号:
- 批准年份:2022
- 资助金额:55 万元
- 项目类别:面上项目
家庭处境不利青少年非自杀性自伤潜在发展结局预测及分阶段匹配干预研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
闪电先导和回击阶段针状结构发生发展特征差异研究
- 批准号:42275090
- 批准年份:2022
- 资助金额:55.00 万元
- 项目类别:面上项目
新发展阶段下相对贫困治理与共同富裕的耦合协同及其驱动机制研究
- 批准号:42271190
- 批准年份:2022
- 资助金额:49 万元
- 项目类别:面上项目
家庭处境不利青少年非自杀性自伤潜在发展结局预测及分阶段匹配干预研究
- 批准号:72204065
- 批准年份:2022
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
相似海外基金
SBIR Phase I: Development of wearable medical device to detect and treat opioid overdose.
SBIR 第一阶段:开发可穿戴医疗设备来检测和治疗阿片类药物过量。
- 批准号:
2335577 - 财政年份:2024
- 资助金额:
$ 25.59万 - 项目类别:
Standard Grant
SBIR Phase I: Industrial-Scale Technology for Drug Development in Mature Human Fat Cells
SBIR 第一阶段:成熟人类脂肪细胞药物开发的工业规模技术
- 批准号:
2322443 - 财政年份:2024
- 资助金额:
$ 25.59万 - 项目类别:
Standard Grant
SBIR Phase II: Development of a Novel Measurement Technology to Enable Longitudinal Multiomic Investigations of the Gut Microbiome
SBIR 第二阶段:开发新型测量技术以实现肠道微生物组的纵向多组学研究
- 批准号:
2314685 - 财政年份:2024
- 资助金额:
$ 25.59万 - 项目类别:
Cooperative Agreement
SBIR Phase I: Development of a SERS-based diagnostic platform for multiplexing ubiquitous inflammatory markers in cancer.
SBIR 第一阶段:开发基于 SERS 的诊断平台,用于多重癌症中普遍存在的炎症标记物。
- 批准号:
2348543 - 财政年份:2024
- 资助金额:
$ 25.59万 - 项目类别:
Standard Grant
SBIR Phase II: Adaptable Ad Hoc Network Architecture for Rapid Infrastructure Development in Disaster Zones
SBIR 第二阶段:用于灾区快速基础设施开发的适应性 Ad Hoc 网络架构
- 批准号:
2322049 - 财政年份:2023
- 资助金额:
$ 25.59万 - 项目类别:
Cooperative Agreement